Arquivos Brasileiros de Endocrinologia & Metabologia
On-line version ISSN 1677-9487
SANTORO, Massimo and FUSCO, Alfredo. New drugs in thyroid cancer. Arq Bras Endocrinol Metab [online]. 2007, vol.51, n.5, pp. 857-861. ISSN 1677-9487. http://dx.doi.org/10.1590/S0004-27302007000500025.
This review is focused on "new drugs" that might be developed for thyroid cancer treatment. Thyroid cancer is frequently associated to the activation of specific protein (RET, BRAF) and lipid [PI(3)K] kinases. There is good evidence that these genetic lesions are causative events in thyroid cancer initiation or progression. Therefore, novel compounds able to target these kinases might be useful for thyroid cancer treatment. The power of this approach is witnessed by the examples of BCR-ABL, c-KIT and EGFR inhibitors in the treatment of chronic myelogenous leukemia (CML), gastro-intestinal stromal tumors (GIST) and non-small cell lung carcinoma (NSCLC).
Keywords : Thyroid cancer; Lipid kinases; RET; BRAF; Cancer therapy.